METTL1/WDR4-mediated tRNA m 7 G modification and mRNA translation control promote oncogenesis and doxorubicin resistance

Zhaoyu Wang,Peng Yu,Yutong Zou,Jieyi Ma,Hui Han,Wei Wei,Chunlong Yang,Siyi Zheng,Siyao Guo,Juan Wang,Lianlian Liu,Shuibin Lin
DOI: https://doi.org/10.1038/s41388-023-02695-6
IF: 8.756
2023-04-26
Oncogene
Abstract:Osteosarcoma is the most common bone tumor that leads to high mortality in adolescents and children. The tRNA N 7 -methylguanosine methyltransferase METTL1 is located in chromosome 12q14.1, a region that is frequently amplified in osteosarcoma patients, while its functions and underlying mechanisms in regulation of osteosarcoma remain unknown. Herein we show that METTL1 and WDR4 are overexpressed in osteosarcoma and associated with poor patient prognosis. Knockdown of METTL1 or WDR4 causes decreased tRNA m 7 G modification level and impairs osteosarcoma progression in vitro and in vivo. Conversely, METTL1/WDR4 overexpression promotes osteosarcoma proliferation, migration and invasion capacities. tRNA methylation and mRNA translation profiling indicate that METTL1/WDR4 modified tRNAs enhance translation of mRNAs with more m 7 G tRNA-decoded codons, including extracellular matrix (ECM) remodeling effectors, which facilitates osteosarcoma progression and chemoresistance to doxorubicin. Our study demonstrates METTL1/WDR4 mediated tRNA m 7 G modification plays crucial oncogenic functions to enhance osteosarcoma progression and chemoresistance to doxorubicin via alteration of oncogenic mRNA translation, suggesting METTL1 inhibition combined with chemotherapy is a promising strategy for treatment of osteosarcoma patients.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?